schizophrenia
Researchers found that discovering progression to schizophrenia via machine learning based on routine clinical data is 'feasible.'
The companies first partnered in 2020 to develop a prescription digital therapeutic for schizophrenia. They said a treatment strategy for the condition "would benefit from a multi-product approach."
The results will not impact the current rollout of a new version of the app, under special FDA guidelines.
The study’s results suggest that social media data can be used in addition to clinical assessment to support decision-making.
The companies will be collaborating on a prescription digital therapeutic for patients with schizophrenia built on Click Therapeutics' tech platform.
The new tool will be released for limited distribution and will provide multimodal neurobehavioral interventions.